• BMB Reports
• /
• v.53 no.12
• /
• pp.634-639
• /
• 2020

In prostate cancer, the androgen receptor (AR) transcription factor is a major regulator of cell proliferation and metastasis. To identify new AR regulators, we focused on Mixed lineage leukemia 5 (MLL5), a histone-regulating enzyme, because significantly higher MLL5 expression was detected in prostate cancer tissues than in matching normal tissues. When we expressed shRNAs targeting MLL5 gene in prostate cancer cell line, the growth rate and AR activity were reduced compared to those in control cells, and migration ability of the knockdown cells was reduced significantly. To determine the molecular mechanisms of MLL5 on AR activity, we proved that AR physically interacted with MLL5 and other co-factors, including SET-1 and HCF-1, using an immunoprecipitation method. The chromatin immunoprecipitation analysis showed reduced binding of MLL5, co-factors, and AR enzymes to AR target gene promoters in MLL5 shRNA-expressing cells. Histone H3K4 methylation on the AR target gene promoters was reduced, and H3K9 methylation at the same site was increased in MLL5 knockdown cells. Finally, xenograft tumor formation revealed that reduction of MLL5 in prostate cancer cells retarded tumor growth. Our results thus demonstrate the important role of MLL5 as a new epigenetic regulator of AR in prostate cancer.

• Biomolecules & Therapeutics
• /
• v.27 no.2
• /
• pp.201-209
• /
• 2019

Mixed lineage leukemia proteins (MLL) are the key histone lysine methyltransferases that regulate expression of diverse genes. Aberrant activation of MLL promotes leukemia as well as solid tumors in humans, highlighting the urgent need for the development of an MLL inhibitor. We screened and isolated MLL1-binding ssRNAs using SELEX (${\underline{S}}ystemic$ ${\underline{E}}volution$ of ${\underline{L}}igands$ by ${\underline{E}}xponential$ enrichment) technology. When sequences in sub-libraries were obtained using next-generation sequencing (NGS), the most enriched aptamers-APT1 and APT2-represented about 30% and 26% of sub-library populations, respectively. Motif analysis of the top 50 sequences provided a highly conserved sequence: 5'-A[A/C][C/G][G/U][U/A]ACAGAGGG[U/A]GG[A/C] GAGUGGGU-3'. APT1, APT2, and APT5 embracing this motif generated secondary structures with similar topological characteristics. We found that APT1 and APT2 have a good binding activity and the analysis using mutated aptamer variants showed that the site information in the central region was critical for binding. In vitro enzyme activity assay showed that APT1 and APT2 had MLL1 inhibitory activity. Three-dimensional structure prediction of APT1-MLL1 complex indicates multiple weak interactions formed between MLL1 SET domain and APT1. Our study confirmed that NGS-assisted SELEX is an efficient tool for aptamer screening and that aptamers could be useful in diagnosis and treatment of MLL1-mediated diseases.

• Speech Sciences
• /
• v.8 no.3
• /
• pp.161-172
• /
• 2001

Ankyloglossia (tongue-tie) limits movement of the tongue connected with feeding and has adverse impacts on both dental health and speech. For the patients with ankyloglossia, surgical intervention is recommended as primary treatment. This study suggests the efficient tool in determining indicatory factors for frenulotomy by quantifying Maximum Lingual Length-Protrusion (MLL-P) with boley gauge, and as a preliminary study, to show the measurement results with normal children using the tool. The subjects were 61 normal children, and the distance (MLL-P) between mandibular central incisor and tongue tip during tongue protrusion was measured with a boley gauge (Digimatic $Caliper^{(R)}$). The results of this study can be summarized as follows: (1) The mean value of MLL-P (N=61 normal children) was 21.44 mm, (2) The mean value of MLL-P was 20.69 mm in males (N=33) and 21.91 mm in females (N=28). There was no statistically significant difference between males and females, (3) The mean value of MLL-P was 19.34 mm, 21.19 mm, 22.33 mm, 22.61 mm for measurement of 3-, 4-, 5- and 6-year-old children, respectively, and (4) The mean value of MLL-P showed statistically significant difference between 3- and 5-year-old children, between 3- and 6-year old children.

• Molecules and Cells
• /
• v.41 no.5
• /
• pp.444-453
• /
• 2018

Aberrations in histone modifications are being studied in mixed-lineage leukemia (MLL)-AF9-driven acute myeloid leukemia (AML). In this study, we focused on the regulation of the differentiation of the MLL-AF9 type AML cell line THP-1. We observed that, upon phorbol 12-myristate 13-acetate (PMA) treatment, THP-1 cells differentiated into monocytes by down-regulating Aurora kinase A (AURKA), resulting in a reduction in H3S10 phosphorylation. We revealed that the AURKA inhibitor alisertib accelerates the expression of the H3K27 demethylase KDM6B, thereby dissociating AURKA and YY1 from the KDM6B promoter region. Using Flow cytometry, we found that alisertib induces THP-1 differentiation into monocytes. Furthermore, we found that treatment with the KDM6B inhibitor GSK-J4 perturbed the PMA-mediated differentiation of THP-1 cells. Thus, we discovered the mechanism of AURKA-KDM6B signaling that controls the differentiation of THP-1 cells, which has implications for biotherapy for leukemia.

• Asian Pacific Journal of Cancer Prevention
• /
• v.16 no.9
• /
• pp.3817-3825
• /
• 2015

Background: The human protein methyl-transferase DOT1L catalyzes the methylation of histone H3 on lysine 79 (H3K79) at homeobox genes and is also involved in a number of significant processes ranging from gene expression to DNA-damage response and cell cycle progression. Inhibition of DOT1L activity by shRNA or small-molecule inhibitors has been established to prevent proliferation of various MLL-rearranged leukemia cells in vitro, establishing DOT1L an attractive therapeutic target for mixed lineage leukemia (MLL). Most of the drugs currently in use for the MLL treatment are reported to have low efficacy, hence this study focused on various natural compounds which exhibit minimal toxic effects and high efficacy for the target receptor. Materials and Methods: Structures of human protein methyl-transferase DOT1L and natural compound databases were downloaded from various sources. Virtual screening, molecular docking, dynamics simulation and drug likeness studies were performed for those natural compounds to evaluate and analyze their anti-cancer activity. Results: The top five screened compounds possessing good binding affinity were identified as potential high affinity inhibitors against DOT1L's active site. The top ranking molecule amongst the screened ligands had a Glide g-score of -10.940 kcal/mol and Glide e-model score of -86.011 with 5 hydrogen bonds and 12 hydrophobic contacts. This ligand's behaviour also showed consistency during the simulation of protein-ligand complex for 20000 ps, which is indicative of its stability in the receptor pocket. Conclusions: The ligand obtained out of this screening study can be considered as a potential inhibitor for DOT1L and further can be treated as a lead for the drug designing pipeline.

• Proceedings of the Korean Institute of Industrial Safety Conference
• /
• 1998.05a
• /
• pp.131-135
• /
• 1998

사용이 편리하고 깨끗한 에너지에 내한 선호도가 증가하면서 가스의 보급이 금속히 확대되었을 뿐만 아니라 향후에도 지속적인 증가 추세를 보일 것으로 보인다. 특히 연탄ㆍ유류ㆍLP가스의 사용이 감소하면서 도시가스의 보급률은 전체 수용가구가 '98년에 624만 7천 가구로 49.2％의 전국 보급률을 갖고 있다. 또한 배관의 총 길이는 15,357km로 과거 5년 전 보다 2배정도 증가하였으며 시설 또한 증가 추세이다. 따라서 도시 가스를 각 가정, 사업장 등에 공급하기 위한 배관의 설치를 산업의 발달로 지하공간을 이용한 공사가 점차적으로 확산되고 있다. (중략)

• Journal of Embryo Transfer
• /
• v.13 no.3
• /
• pp.245-249
• /
• 1998

The purpose of this study was to evaluate the effects of growth factors such as epidermal growth factor (EGF) and insulin-like growth factor-1 (IGF-1) on maturation of bovine follicular oocytes in vitro. Oocytes were recovered from the ovaries of slaughtered Hanwoos. The oocytes were matured in TCM 199 at 39$^{\circ}C$, 5% $CO_2$ in air. Growth factors were added to maturation medium as follows: control (no serum), EGF (10ng/m1, 50ng/ml or 100ng/m1), IGF-1 (100ng/m1) and EGF (50ng/ml) + IGF-1 (100ng/m1). The oocytes were placed onto a slide and stained with aceto-orcein dye. Nuclear maturation was evaluated and classified as germinal vesicle breakdown (GVBD), metaphase-I (MI) or metaphase-ll(Mll). Maturation rates were 37.9% (control), 45.8% (EGF, 10ng/m1), 55.8% (EGF, 50ng/ml), 44.4% (EGF, 100ng/m1), 46.7% (IGF-1, 100ng/m1) and 67.0% (IGF-1+EGF). The highest group developed to Mll stage was IGF-1+EGF treatment group (p<0.05). Therefore, nuclear maturation of bovine oocytes were affected by both of growth factors, and it seems to have a mutual activity between them.

• Asian Pacific Journal of Cancer Prevention
• /
• v.13 no.11
• /
• pp.5469-5475
• /
• 2012

Background and Objectives: Acute lymphoblastic leukemia (ALL) is a complex genetic disease involving many fusion oncogenes (FO) having prognostic significance. The frequency of various FO can vary in different ethnic groups, with important implications for prognosis, drug selection and treatment outcome. Method: We studied fusion oncogenes in 101 pediatric ALL patients using interphase FISH and RT-PCR, and their associations with clinical features and treatment outcome. Results: Five most common fusion genes i.e. BCR-ABL t (22; 9), TCF3-PBX1 (t 1; 19), ETV6-RUNX1 (t 12; 21), MLL-AF4 (t 4; 11) and SIL-TAL1 (del 1p32) were found in 89/101 (88.1%) patients. Frequency of BCR-ABL was 44.5% (45/101). BCR-ABL positive patients had a significantly lower survival ($43.7{\pm}4.24$ weeks) and higher white cell count as compared to others, except patients with MLL-AF4. The highest relapse-free survival was documented with ETV6-RUNX1 (14.2 months) followed closely by those cases in which no gene was detected (13.100). RFS with BCR-ABL, MLL-AF4, TCF3-PBX1 and SIL-TAL1 was less than 10 months (8.0, 3.6, 5.5 and 8.1 months, respectively). Conclusions: This is the first study from Pakistan correlating molecular markers with disease biology and treatment outcome in pediatric ALL. It revealed the highest reported frequency of BCR-ABL FO in pediatric ALL, associated with poor overall survival. Our data indicate an immediate need for incorporation of tyrosine kinase inhibitors in the treatment of BCR-ABL+ pediatric ALL in this population and the development of facilities for stem cell transplantation.

• Clinical and Experimental Pediatrics
• /
• v.60 no.5
• /
• pp.129-137
• /
• 2017

The event-free survival (EFS) for pediatric acute lymphoblastic leukemia (ALL) has shown remarkable improvement in the past several decades. In Korea also, a recent study showed 10-year EFS of 78.5%. Much of the improved outcome for pediatric ALL stems from the accurate identification of prognostic factors, the designation of risk group based on these factors, and treatment of appropriate duration and intensity according to risk group, done within the setting of cooperative clinical trials. The schema of first-line therapy for ALL remains mostly unchanged, although many groups have now reported on the elimination of cranial irradiation in all patients with low rates of central nervous system relapse. Specific high risk subgroups, such as Philadelphia chromosome-positive (Ph+) ALL and infant ALL continue to have significantly lower survival than other ALL patients. The introduction of tyrosine kinase inhibitors into therapy has led to enhanced outcome for Ph+ ALL patients. Infant ALL patients, particularly those with MLL rearrangements, continue to have poor outcome, despite treatment intensification including allogeneic hematopoietic cell transplantation. Relapsed ALL is a leading cause of mortality in pediatric cancer. Recent advances in immunotherapy targeting the CD19 of the ALL blast have shown remarkable efficacy in some of these relapsed and refractory patients. With improved survival, much of the current focus is on decreasing the long-term toxicities of treatment.

• Asian Pacific Journal of Cancer Prevention
• /
• v.13 no.7
• /
• pp.3349-3355
• /
• 2012

Background and objectives: Chromosomal abnormalities play an important role in genesis of acute lymphoblastic leukemia (ALL) and have prognostic implications. Five major risk stratifying fusion genes in ALL are BCR-ABL, MLL-AF4, ETV6-RUNX11, E2A-PBX1 and SIL-TAL1. This work aimed to detect common chromosomal translocations and associated fusion oncogenes in adult ALL patients and study their relationship with clinical features and treatment outcome. Methods: We studied fusion oncogenes in 104 adult ALL patients using RT-PCR and interphase-FISH at diagnosis and their association with clinical characteristics and treatment outcome. Results: Five most common fusion genes i.e. BCR-ABL (t 9; 22), TCF3-PBX1 (t 1; 19), ETV6-RUNX1 (t 12; 21), MLL-AF4 (t 4; 11) and SIL-TAL1 (Del 1p32) were found in 82/104 (79%) patients. TCF3-PBX1 fusion gene was associated with lymphadenopathy, SIL-TAL1 positive patients had frequent organomegaly and usually presented with a platelets count of less than $50{\times}10^9/l$. Survival of patients with fusion gene ETV6-RUNX1 was better when compared to patients harboring other genes. MLL-AF4 and BCR-ABL positivity characterized a subset of adult ALL patients with aggressive clinical behaviour and a poor outcome. Conclusions: This is the first study from Pakistan which investigated the frequency of5 fusion oncogenes in adult ALL patients, and their association with clinical features, treatment response and outcome. Frequencies of some of the oncogenes were different from those reported elsewhere and they appear to be associated with distinct clinical characteristics and treatment outcome. This information will help in the prognostic stratification and risk adapted management of adult ALL patients.